2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec ODT—entered the market in rapid succession, becoming the first novel, migraine-specific therapies to be approved in the acute segment in nearly two decades. Meanwhile a range of additional acute products are advancing through late-phase development. This report assesses how U.S. physicians and payers will react to new, premium-priced brands entering a mostly generic market, and how payer policies will affect physicians’ adoption.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Survey of 100 U.S. physicians (including 50 neurologists and 50 PCPs).
Survey of 31 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
Formulary coverage and restrictions data for acute migraine therapies by commercial plans covering approximately 168 million lives nationally.
Key Drugs Covered
Reyvow (lasmiditan), Ubrelvy (ubrogepant), Nurtec ODT (rimegepant), Elyxyb, AXS-07, Rizaport, Qtrypta, INP104, STS101, zavegepant (vazegepant), current SoC treatments.